1887236-33-0
Chemical Structure
Verducatib
- CAS No.: 1887236-33-0
- Formula:C31H35FN4O3
- Molecular Weight:530.63
InChIKey: MIBKKDLVBYJWTB-AIKBEYBBSA-N
SMILES: FC1=C(C[C@@H](C#N)NC([C@@H]2[C@]3([H])C[C@](CC3)([H])N2)=O)C=CC(C4=CC=C5COC6(CCN(C7COC7)CC6)C5=C4)=C1
Biological Activity: Verducatib (BI 1291583) is an orally active inhibitor of cathepsin C (also known as DPP1). Verducatib restores the protease-inhibitor balance by inhibiting the activation of neutrophil serine proteases, thereby alleviating pulmonary inflammation and regulating infection responses. Verducatib significantly reduces the risk (including severe exacerbations) and frequency of acute exacerbations in bronchiectasis (BE). Verducatib also improves lung function and quality of life, and shortens the duration of antibiotic use. The overall incidence of adverse events of Verducatib is comparable to that of placebo, with only slightly more mild-to-moderate cutaneous adverse events observed in the high-dose group, demonstrating promising clinical application potential[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Verducatib | 98.94% | Verducatib (BI 1291583) is an orally active inhibitor of cathepsin C (also known as DPP1). Verducatib restores the protease-inhibitor balance by inhibiting the activation of neutrophil serine proteases, thereby alleviating pulmonary inflammation and regulating infection responses. Verducatib significantly reduces the risk (including severe exacerbations) and frequency of acute exacerbations in bronchiectasis (BE). Verducatib also improves lung function and quality of life, and shortens the duration of antibiotic use. The overall incidence of adverse events of Verducatib is comparable to that of placebo, with only slightly more mild-to-moderate cutaneous adverse events observed in the high-dose group, demonstrating promising clinical application potential. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Chalmers J D, et al. Study design of a Phase III study (AIRTIVITY) of the novel dipeptidyl peptidase 1 (cathepsin C) inhibitor verducatib in people with bronchiectasis[J]. Pneumologie, 2026, 80(S 01): P 2026-464.
- [2]. Kreideweiss S, et al. BI 1291583: a novel selective inhibitor of cathepsin C with superior in vivo profile for the treatment of bronchiectasis[J]. Inflammation Research, 2023, 72(8): 1709-1717.
Keywords
